Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.

Abstract

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of (10)B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg).

• Authors: T Andoh, T Fujimoto, T Sudo, I Fujita, M Imabori, H Moritake, T Sugimoto, Y Sakuma, T Takeuchi, S Kawabata, M Kirihata, T Akisue, K Yayama, M Kurosaka, S Miyatake, Y Fukumori, H Ichikawa
• Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine (Appl Radiat Isot) Vol. 69 Issue 12 Pg. 1721-4 (Dec 2011) ISSN: 1872-9800 [Electronic] England
• PMID: 21367607 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Boron Compounds
• Phenylalanine
• 4-boronophenylalanine

Topics

• Adolescent
• Animals
• Boron Compounds (pharmacokinetics)
• Boron Neutron Capture Therapy
• Cell Line, Tumor
• Female
• Humans
• Mice
• Mice, Inbred BALB C
• Mice, Nude
• Phenylalanine (analogs & derivatives, pharmacokinetics)
• Sarcoma, Clear Cell (metabolism, radiotherapy)
• Tissue Distribution